State of the Union

State of the Union

Business & Finance

Information

On 18 May, flanders.bio is organising the 8th edition of their State of the Union with VIB; a moment to announce new developments and initiatives in the Flemish life sciences cluster and how we position ourselves vis-a-vis the European landscape. After several inspiring talks and discussions, there will be plenty of networking opportunities, accompanied by fine food and drinks.

Separate registration is required!


17h00 - doors

17h30 - start programme

19h00 - networking reception / hosted by Enterprise Ireland


Programme

  • Welcome by flanders.bio
  • Health check unlisted companies - Kenneth Wils, Head of Life Sciences & Care, PMV
  • Presentation Legend Biotech - Birk Vanderweeën, CEO, Legend Biotech Belgium
  • Young company pitches:
  1. Karine Clauwaert, CEO, Abscint
  2. Tom Bosschaerts, Co-Founder, Immunewatch
  3. Elien Van Hecke, Founder & CCO, Fertiga
  • Solvay: ‘Advanced Master in Biotech & MedTech Ventures’ - Marc Dechamps, Academic Director, Solvay Brussels School of Economics and Management
  • Presentation ‘biotope by VIB’ - Tony Montoye, biotope Manager, VIB
  • Positioning listed companies - Nathalie van Den Haute, Executive Director Corporate Finance, KBC Securities
  • Closing words - Jérôme Van Biervliet, Managing Director, VIB
VIBbooth 58VIB’s core mission is to generate disruptive insights in the molecular underpinning of life and to translate these actively into impactful innovations for patients and society. VIB is an independent research institute where some 1,800 top scientists from Belgium and abroad conduct pioneering basic research. As such, they are pushing the boundaries of what we know about molecular mechanisms and how they rule living organisms such as human beings, animals, plants, and microorganisms. Based on a close partnership with five Flemish universities – Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel, and Hasselt University – and supported by a solid funding program, VIB unites the expertise of all its collaborators and research groups in a single institute. VIB’s technology transfer activities translate research results into concrete benefits for society such as new diagnostics and therapies and agricultural innovations. These applications are often developed by young start-ups from VIB or through collaborations with other companies. This also leads to additional employment and bridges the gap between scientific research and entrepreneurship. Since its foundation, VIB has created 34 start-up companies. VIB also engages actively in the public debate on biotechnology by developing and disseminating a wide range of science-based information. More info can be found on www.vib.be.

Log in